REG - Futura Medical PLC - Block Listing Six Monthly Return

Futura MedicalAnnouncement

Mon 15:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250602:nRSB0774La&default-theme=true

RNS Number : 0774L  Futura Medical PLC  02 June 2025

2 June 2025

Futura Medical plc

("Futura" or the "Company")

Block Listing Six Monthly Return

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon,
that specialises in the development and global commercialisation of
innovative and clinically proven sexual health products, makes the following
update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the
AIM Rules for Companies. All figures relate to options over Ordinary Shares of
0.2 pence each (Ordinary Shares).

Date: 2 June 2025

 Name of applicant:                                                                Futura Medical Plc
 Name of scheme(s):                                                                Unapproved Share Option Scheme

                                                                                   Unapproved Share Incentive Scheme

                                                                                   EMI Share Option Scheme

                                                                                   LTIP Scheme
 Period of return:                        From:                                    1 December 2024     To:                 31 May 2025
 Balance of unallotted securities under scheme(s) from previous return:            18,528,545
 Plus:  The amount by which the block scheme(s) has been increased since the       USOS: nil
 date of the last return (if any increase has been applied for):

                                                                                   USIS: nil

                                                                                   EMI: nil

                                                                                   LTIP: nil
 Less:  Number of securities issued/allotted under scheme(s) during period:        USOS: nil

                                                                                   USIS: nil

                                                                                   EMI: nil

                                                                                   LTIP: nil

 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        18,528,545
 Number and class of securities originally admitted and the date of admission      USOS Total: 3,882,912

                                                                                   814,424 25 May 2011

                                                                                   1,202,280             8 October 2013

                                                                                   1,466,208             25 May 2017

                                                                                   400,000 30 May 2018

                                                                                   USIS Total: 425,000

                                                                                   425,000 30 November 2018

                                                                                   EMI Total: 8,112,088

                                                                                   1,520,576             25 May 2011

                                                                                   1,467,720             8 October 2013

                                                                                   1,893,792             25 May 2017

                                                                                   790,000 30 May 2018

                                                                                   1,340,000             30 November 2018

                                                                                   1,100,000           2 February 2023

                                                                                   LTIP Total:  15,035,617

                                                                                   4,444,942            2 February 2023

                                                                                   10,590,675          3 November 2023

 

Contacts:

 Futura Medical plc             James Barder                                                           investor.relations@futuramedical.com

                                                                      (mailto:Investor.relations@futuramedical.com)
                                Chief Executive Officer

                                                                      +44 (0)1483 685 670
                                Angela Hildreth

                                                                      www.futuramedical.com (http://www.futuramedical.com/)
                                Finance Director and COO

 Panmure Liberum                Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden  +44 (0)20 3100 2000

                              (Corporate Broking)

 Nominated Adviser

 and Broker

 Alma Strategic Communications  Rebecca Sanders-Hewett                                                 +44 (0)20 3405 0205

                                Sam Modlin                                                             futura@almastrategic.com

                                Will Ellis Hancock

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon® and products WSD4000 and
Eroxon® Intense. Our core strength lies in our research, development and
commercialisation of topically delivered gel formulations in sexual health
products.

Sexual health issues are prevalent in both men and women. ED impacts 1 in 5
men globally across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men under 40.
Around 60% of women experience at least one symptom of sexual dysfunction, and
only one in four women seek professional help, and remain chronically
underserved.

Eroxon®, Futura's clinically proven lead product, has been developed for the
treatment of Erectile Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the counter and
helps men get an erection in ten minutes, addresses significant unmet needs in
the ED market. Eroxon® has been nominated for a number of healthcare
industry awards and has won two to-date.

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRUURSRVWUNRAR